SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
June 02, 2022 08:30 ET
|
SciSparc Ltd
No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...
Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
May 27, 2022 07:15 ET
|
Purple Biotech Ltd.
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT, Israel, May 27, 2022 (GLOBE NEWSWIRE) --...
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
May 26, 2022 08:30 ET
|
SciSparc Ltd
Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in Germany and Israel TEL AVIV, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC)...
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
April 05, 2022 07:15 ET
|
Claritas Pharmaceuticals, Inc.
SAN FRANCISCO, CA and TORONTO, ON, April 05, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the "Company" or "Claritas") today announced that...
Truveta announces new COVID-19 insights and unveils Truveta platform for the first time at #ViVE2022
March 08, 2022 12:04 ET
|
Truveta
Bellevue, WASH, March 08, 2022 (GLOBE NEWSWIRE) -- Truveta, the health system-led company with a vision of saving lives with data, unveiled the Truveta platform in its first public demonstration at...
Ananda Professional is Opening Enrollment to Participate in an IRB-Approved Phase IV Clinical Trial Investigating How CBD May Benefit Women's Health and Wellness
March 07, 2022 13:00 ET
|
Ananda Professional
GEORGETOWN, Ky., March 07, 2022 (GLOBE NEWSWIRE) -- Ananda Professional has committed $40 million to advance the clinical evidence of hemp extract through clinical research. As part of this...
Faro Health Inc. Expands Leadership Team and Announces Participation at SCOPE, Following Its $15 Million Series A Funding
February 03, 2022 05:00 ET
|
Faro Health Inc
LA JOLLA, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Faro Health, the clinical protocol solutions company, today announced that it has strengthened its leadership team with the appointment of...
Love Pharma’s Acquisition Will Offer Exclusive Partnership and License with World Renowned University to Conduct Landmark Psilocybin Study
November 30, 2021 08:50 ET
|
Love Pharma Inc.
NEW YORK, NY, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) continues to prioritize the necessity for clinical validation as a vital step in bringing its products to...
eSight Announces Clinical Research Partnership with Ocular Health Centre’s EyeStart Inc.
October 20, 2021 09:00 ET
|
eSight
TORONTO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Leading vision-enhancement platform, eSight, today announces a new research and development partnership with the Ocular Health Centre, one of Ontario’s top...
RIVANNA's Accuro Shows Statistically Significant Efficacy and Safety for Combined Spinal-Epidural Anesthesia
September 27, 2021 06:00 ET
|
Rivanna Medical
CHARLOTTESVILLE, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- RIVANNA®, developers of world-first, imaging-based medical solutions, today announced the results of a recent randomized controlled trial...